Clarke L A, Nelson P V, Warrington C L, Morris C P, Hopwood J J, Scott H S
Department of Medical Genetics, University of British Columbia, Vancouver, Canada.
Hum Mutat. 1994;3(3):275-82. doi: 10.1002/humu.1380030316.
Mucopolysaccharidosis type I (MPS I) is an autosomal recessive genetic disorder caused by deficiency of the lysosomal glycosidase alpha-L-iduronidase. Patients with this disorder present with varied clinical phenotypes ranging from early severe onset of disease and death in early childhood to mild manifestations compatible with adult life. An understanding of the molecular basis of iduronidase deficiency and its correlation to clinical phenotype will improve prognostic prediction at diagnosis, aid in genetic counselling of families, and provide a framework to more accurately assess experimental treatment protocols. We have used the approach of single-strand conformational polymorphism analysis and direct sequencing of the alpha-L-iduronidase gene in an attempt to define the molecular basis of iduronidase deficiency in affected individuals. An initial series of 19 patients representing 35 independently segregating mutant alleles were studied. In addition to five previously identified mutations (W402X, Q70X, E274X, H82P, and P533R) two novel mutations (A75T and 474-2a-->g) were found. These seven mutations account for 71% of the mutant alleles and 53% of the genotypes in this group of patients. Analysis of a larger independently ascertained group of 103 MPS I patients, mainly of Northern European origin, revealed that together the two novel mutations account for 7% of mutant alleles and are associated with severe clinical phenotypes. These mutations are the most frequent MPS I mutations detected so far after W402X and Q70X. With the definition of these two mutations, a clear picture of the molecular heterogeneity of MPS I is emerging.
I型黏多糖贮积症(MPS I)是一种常染色体隐性遗传疾病,由溶酶体糖苷酶α-L-艾杜糖醛酸酶缺乏所致。该疾病患者临床表现各异,从疾病早期严重发作并在儿童早期死亡到与成年生活相符的轻度表现不等。了解艾杜糖醛酸酶缺乏的分子基础及其与临床表型的相关性将改善诊断时的预后预测,有助于家庭的遗传咨询,并为更准确地评估实验性治疗方案提供框架。我们采用单链构象多态性分析和α-L-艾杜糖醛酸酶基因直接测序的方法,试图确定受影响个体中艾杜糖醛酸酶缺乏的分子基础。对代表35个独立分离突变等位基因的19例患者进行了初步研究。除了先前确定的5个突变(W402X、Q70X、E274X、H82P和P533R)外,还发现了2个新突变(A75T和474-2a→g)。这7个突变占该组患者突变等位基因的71%和基因型的53%。对另一组更大的、主要来自北欧的103例独立确诊的MPS I患者进行分析发现,这2个新突变共同占突变等位基因的7%,并与严重临床表型相关。这些突变是迄今为止在W402X和Q70X之后检测到的最常见的MPS I突变。随着这两个突变的确定,MPS I分子异质性的清晰图景正在显现。